Ventyx Biosciences soars as report says Eli Lilly eyes $1 billion acquisition

Ventyx Biosciences

07/01/2026 10:09

** Shares of drug developer Ventyx Biosciences VTYX.O surge 67% to $16.79 premarket

** Eli Lilly LLY.N in advanced talks to buy VTYX for more than $1 billion, WSJ reported on Tuesday

** Potential agreement will add drugs for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, to Lilly's pipeline

** Stock soared roughly 220% to $25 immediately following the report on Tuesday, before Nasdaq temporarily halted trading on the stock

** VTYX closed Tuesday up 28.5%, with a market cap of $717.15 million - data compiled by LSEG

** VTYX stock more than quadrupled in 2025

(Reporting by Utkarsh Tushar Hathi)

((utkarshtushar.hathi@thomsonreuters.com))